Mediterr J Rheumatol 2020;31(Supp 1):100-4
Basic Mechanisms of JAK Inhibition
Authors Information

Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom

  1. O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus Kinase inhibitors in autoimmune disease. Ann Rheum Dis 2013 Apr;72(0 2):ii111-ii115.
  2. Rein P, Mueller RB. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. Rheumatol Ther 2017 Dec;4(2):247-61.
  3. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signalling. Immunol Rev 2009 Mar;228(1):273-87.
  4. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis? Ann Rheum Dis 2018 Feb;77(2):175-87.
  5. Malemud CJ. The Role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskel Dis 2018, Vol. 10(5-6) 117-27.
  6. Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol 2016 Jan;12(1):25-36.
  7. O’Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A. The JAK-STAT pathway: Impact on Human Disease and Therapeutic Intervention. Annu Rev Med 2015;66:311-28.
  8. Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, et al. The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. J Allergy Clin Immunol 2018 Jan;141(1):445-448.e4.
  9. Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs 2019 Feb;33(1):15-32.
  10. Boulay JL, O’Shea JJ, Paul WE. Molecular Phylogeny within Type I Cytokines and Their Cognate Receptors. Immunity 2003 Aug;19(2):159-63.
  11. Kontzias A, Kotlyar A, Laurence A, Changelian P, O'Shea JJ. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseases. Curr Opin Pharmacol 2012;12:464-70.
  12. Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O'Shea JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;16:843-62.
  13. O’Shea JJ, Pesu M, Borie DC, Changelian PS. A New Modality for Immunosuppression: Targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004 Jul;3(7):555-64.
  14. Gupta R, Gupta SK. Severe Hepatotoxicity in a Rheumatoid Arthritis Patient Switched From Leflunomide to Methotrexate. MedGenMed 2005;7(3):9.
  15. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, et al. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:583-9.
  16. Van Vollenhoven RF. Unresolved issues in biologic therapy for rheumatoid arthritis. Nat Rev Rheumatol 2011 Apr;7(4):205-15.
  17. Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health 2013 Mar-Apr;16(2):385-93.
  18. Duhé RJ, Farrar WL. Structural and Mechanistic Aspects of Janus Kinases: How the Two-Faced God Wields a Double-Edged Sword. J Interferon Cytokine Res 1998 Jan;18(1):1-15.
  19. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
  20. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012 Apr 20;36(4):503-14.
  21. Casanova JL, Holland SM, Notarangelo LD. Inborn errors of human JAKs and STATs. Immunity 2012;36:515-28.
  22. Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992;70:313-22.
  23. Macchi P, Villa A, Giliani S, Sacco MG, Frattini A, Porta F, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377:65-8.
  24. Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270:797-800.
  25. Meyers SC, Levine RL. Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. Clin Cancer Res 2014 Apr 15;20(8):2051-9.
  26. Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008 Mar;49(3):388-97.
  27. Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs 2013 Oct;27(5):431-8.
  28. Waldmann TA, Chen J. Disorders of the JAK-STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. Annu Rev Immunol 2017; 35:533-50.
  29. Patterson H, Nibbs R, McInnes I, Siebert S. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol 2014 Apr;176(1):1-10.
  30. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125-35.
  31. Raychaudhuri SP, Raychaudhuri SK. Biologics: Target-specific treatment of systemic and cutaneous autoimmune diseases. Indian J Dermatol 2009 Apr-Jun; 54(2):100-9.
  32. Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland (MA): Sinauer Associates; 2000. The Central Role of Enzymes as Biological Catalysts.
  33. Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5th edition. New York: W H Freeman; 2002. Section 8.4, The Michaelis-Menten Model Accounts for the Kinetic Properties of Many Enzymes.
  34. Genovese MC, Smolen JS, Weinblatt ME, Burmester GR, Meerwein S, Camp HS, et al. Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate. Arthritis Rheumatol 2016 Dec;68(12):2857-66.
  35. Fragoulis G, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology 2019;58:i43i54.
  36. Cook N, Hansen, AR, Siu LL, Abdul Razak AR. Early phase clinical trials to identify optimal dosing and safety. Mol Oncol 2015 May;9(5):997-1007.
  37. Ferrao RD, Wallweber HJA, Lupardus PJ. Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation. eLife 2018;7:e38089.
  38. Kiu H, Nicholson SE. Biology and significance of the JAK/STAT signalling pathways. Growth Factors 2012 Apr;30(2):88-106.
  39. Suzuki K, Nakajima H, Saito Y, Saito T, Leonard WJ, Iwamoto I. Janus kinase 3 (Jak3) is essential for common cytokine receptor gamma chain (gamma(c))-dependent signaling: comparative analysis of gamma(c), Jak3, and gamma(c) and Jak3 double-deficient mice. Int Immunol 2000 Feb;12(2):123-32.
  40. Clark JD, Flanagan ME, Telliez J-B. Discovery and Development of Janus Kinase (JAK) inhibitors for Inflammatory Diseases. J Med Chem 2014 Jun 26;57(12):5023-38.
  41. Gadina M, Hilton D, Johnston JA, Morinobu A, Lighvani A, Zhou YJ, et al. Signaling by type I and II cytokine receptors: ten years after. Curr Opin Immunol 2001;13(3):363-73.
  42. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, et al. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 1998;93(3):373-83.
  43. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 1998;93(3):397-409.
  44. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell 1998;93(3):385-95.
  45. Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009 Mar;228(1):273-87.
  46. Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 2017 Apr;13(4):234-43.
  47. McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signalling in human leukocyte subpopulations. Arthritis Res Ther 2019 Aug 2;21(1):183.
  48. Kim H-S, Lee S, Kim J-H. Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records. J Korean Med Sci 2018 Aug 20;33(34):e213.
  49. Kotyla PJ. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients? Biomed Res Int 2018;2018:7492904.
  50. Mok CC. The Jakinibs in systemic lupus erythematosus: progress and prospects. Expert Opin Investig Drugs 2019 Jan;28(1):85-92.
  51. Reynolds G, Cooles FAH, Isaacs JD, Hilkens CM. Emerging immunotherapies for rheumatoid arthritis. Hum Vaccin Immunother 2014 Apr;10(4):822-37.
  52. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004;21:461-5.
  53. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010;10:89-102.
  54. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol 2009;9:556-67.
  55. Cooles FAH, Isaacs JD. Pathophysiology of rheumatoid arthritis. Curr Opin Rheumatol 2011 May;23(3):233-40.